Key facts
- This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2023, 16:15.
Pascal Touchon - 27 Jun 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ATRA
- Reported as of
- 27 Jun 2023
- Net transaction value
- -$23,723
- SEC form
- 4
- Accepted by SEC
- 29 Jun 2023, 16:15:42 UTC
- Prior SEC filing
- 18 May 2023
- Next SEC filing
- 18 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Kiekhofer, Attorney-in-Fact for Pascal Touchon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 29 Jun 2023.
Change
- Previous filing in this sequence was filed on 18 May 2023.
- Current net transaction value: -$23,723.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Sale
- Transaction value
- $23,723
- Shares
- -14,291
- Change %
- -2%
- Price
- $1.66
- Shares after
- 706,671
- Date
- 27 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units.